- Home
- CLLS vs AVIR Comparison
CLLS vs AVIR Comparison
Compare CLLS & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLLS | AVIR |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.3M | 434.5M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CLLS | AVIR |
|---|---|---|
| Price | $3.93 | $5.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $8.33 | ★ $10.00 |
| AVG Volume (30 Days) | 27.9K | ★ 221.5K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $2.46 |
| 52 Week High | $5.48 | $6.45 |
Technical Indicators
Market Signals| Indicator | CLLS | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 54.03 | 49.21 |
| Support Level | $3.93 | $5.13 |
| Resistance Level | $4.48 | $5.83 |
| Average True Range (ATR) | 0.21 | 0.23 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 66.67 | 49.15 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.